{"schema_version":"secwatch.filing_event.v1","accession":"0000885725-24-000070","form_type":"8-K","ticker":"BSX","cik":"0000885725","company_name":"BOSTON SCIENTIFIC CORP","filed_at":"2024-10-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.264704+00:00","generated_at":"2026-05-30T11:19:42.675863+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Boston Scientific Q3 net sales $4.209B (+19.4% reported), adj. EPS $0.63 vs $0.50 YoY","bullets":["Net sales $4.209B, up 19.4% reported, 18.2% organic; beat guidance of 13-15%.","GAAP EPS $0.32 (down from $0.34), adjusted EPS $0.63 (vs guidance $0.57-0.59).","Cardiovascular segment grew 25.0% reported; MedSurg grew 10.3%.","Full-year 2024 organic sales guidance ~15%; Q4 organic guidance 14-16%.","Completed acquisition of Silk Road Medical for stroke prevention."],"urls":{"canonical":"https://secwatch.observer/filing/0000885725-24-000070","json":"https://secwatch.observer/filing/0000885725-24-000070.json","markdown":"https://secwatch.observer/filing/0000885725-24-000070.md","text":"https://secwatch.observer/filing/0000885725-24-000070.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/885725/000088572524000070/0000885725-24-000070-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/885725/000088572524000070/bsx-20241023.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T11:19:42.675863+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}